Therapeutics

Viromids: A Redosable, Low-Cost Gene-Delivery Platform for Ocular Therapy

Overview

Viromids are next-generation gene delivery vectors inspired by naturally occurring, harmless members of the human virome. They overcome the critical barriers that limit today's viral vectors by enabling repeat dosing, delivery of large or multiple genes, and dramatically lower manufacturing costs, all while maintaining exceptional purity and safety.

Problem

Gene therapy can correct disease at its root, yet decades of work with current viral vectors, such as adeno-associated virus (AAV) and lentivirus, have exposed fundamental limitations:

Immune barriers prevent redosing
Many patients are ineligible
Cargo limitations
High cost and limited scalability
Safety concerns persist

Solution

Viromids combine commensal viral safety with bacterial biomanufacturing efficiency, creating a versatile family of scalable, immune-silent delivery vectors.

iPhagemids - derived from a filamentous bacteriophage common to the human gut — tissue-targetable, well-tolerated, non-inflammatory, and customizable for large genetic cargos.
Anellomids Anellomids – derived from an anellovirus—ubiquitous, non-pathogenic inhabitants of human tissues common to all humans’ blood and tissues with lifelong immune tolerance, ideal for repeat dosing.